RATIONALE: Characteristics of AAb+ in patients with IPF have been previously studied; however, the clinical impact of AAb+ is not fully established.

AIMS AND OBJECTIVES: To assess baseline characteristics and clinical outcomes in patients with IPF from the PFF-PR stratified by baseline AAb status.

METHODS: Patients with IPF enrolled in the PFF-PR who had serology records and an IPF diagnosis within 1 year of consent were included (data cut-off: 15 October 2022). Patients were split by AAb status (see table footnote§). Baseline characteristics were assessed. Multivariable analysis was used to examine outcomes such as: time to death or lung transplant; time to >5% decline in %FVC; time to hospitalisation; and time to deterioration.

RESULTS: In total, 87 (27.7%) patients were AAb+. Patient baseline characteristics are reported in the Table; baseline comorbidities were similar. AAb status was not significantly associated with differential transplant-free survival (HR [95% CI] 1.03 [0.7, 1.5]), time to >5% decline in %FVC (0.84 [0.57, 1.25]), time to hospitalisation (0.96 [0.65, 1.41]) or time to deterioration (0.62 [0.37, 1.03]).

CONCLUSIONS: Some baseline characteristics differed between groups. These real-world data suggest that AAb status does not impact outcomes in patients with IPF.